Doximity plunges 24% on weak guidance, analysts slash PTs on increased AI spending

Doximity shares plunged after the company reported weaker-than-expected quarterly profit and delivered fiscal 2027 revenue guidance that fell significantly short of Wall Street estimates. The article points to slowing growth and higher spending tied to AI initiatives as the main investor concerns. The combination of an earnings miss and disappointing outlook is likely to pressure the stock materially.

Analysis

DOCS is being repriced less as a growth story and more as a proof-point that the AI monetization cycle is not yet showing up in durable operating leverage. The key second-order issue is not just slower top-line expectations, but the market’s willingness to pay a premium multiple for a platform whose spend profile is now front-loaded into product development while revenue benefits remain deferred. That combination tends to compress valuation twice: lower near-term estimates and a higher discount rate for future AI payback.

The competitive implication is that incumbents with stronger reimbursement-linked workflows or more embedded enterprise distribution can exploit any pause in DOCS’s momentum. If customers start treating AI features as table stakes rather than differentiation, spend shifts from premium growth names toward vendors that can bundle AI into larger, sticky contracts; that is a relative win for broader healthcare IT platforms and a headwind for point-solution monetization. In the near term, the market will likely punish any company in adjacent digital-health categories that has heavy AI capex but limited evidence of pricing power.

The risk window is measured in months, not days: one weak guide can be reversed only if the next 1-2 quarters show that AI-related spend is translating into accelerating engagement, retention, or cross-sell. If management has to keep funding product development into fiscal 2027 without clear conversion metrics, the multiple can de-rate further even if revenue merely stays stable. Conversely, a sharp bounce is possible if cost discipline returns sooner than expected or if management quantifies AI-driven ARPU uplift with enough specificity to reset investor trust.

Consensus may be underestimating how much of the stock’s premium was tied to perceived operating leverage rather than absolute growth. If that premium was built on a small set of long-duration buyers, the move can overshoot on the downside before stabilizing, especially if quant and momentum holders are forced out. The flip side is that if this is mainly an earnings-guidance reset rather than a demand collapse, the stock could become attractive after the first post-gap stabilization rather than immediately.

Key Decisions for Investors

• Short DOCS on any failed rebound into the next 3-5 sessions; use a tight stop above the post-earnings gap fill, targeting a 2:1 downside/reward if multiple compression continues.
• Pair trade: short DOCS / long a higher-quality healthcare software name with clearer workflow stickiness over a 1-3 month horizon to isolate AI monetization skepticism from sector beta.
• Buy DOCS put spreads 1-2 months out if implied vol remains elevated but not extreme; structure for a move to a lower trading band rather than a full collapse, limiting theta bleed.
• Watch for a tactical long only after management provides explicit AI conversion metrics; until then, treat any 10-15% bounce as a liquidity event rather than a trend reversal.
• Trim exposure to other digital-health names with heavy AI spend and weak FCF visibility over the next earnings season, as DOCS may become the template trade for de-rating risk.